secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001570562-25-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus reports record Q4 2024 revenue $79.0M (+30% YoY); achieves full-year profitability ahead of expectations
--------------------------------------------------------------------------------

- Record Q4 revenue $79.0M (+30% YoY); full-year $266.3M (+32% YoY).
- GAAP op loss improved to $2.3M Q4; non-GAAP op income $6.7M Q4 and $0.3M full year (profitability ahead of schedule).
- Evolysse FDA approval Feb 2025; launch Q2 2025; expected 8-10% of 2025 revenue.
- 2025 revenue guidance $345-355M (30-33% growth); expects positive non-GAAP op income for full year.
- Added ~2,900 new accounts in 2024; total >15,300 accounts; over 50% US account penetration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056225000017/0001570562-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056225000017/eols-20250304.htm
  HTML page:      https://secwatch.observer/filing/0001570562-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer